Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Global Head of Regulatory Affairs for Companion Diagnostics (CDx) will define and lead the end-to-end global regulatory diagnostic strategy for the company’s portfolio. This person will be accountable for the regulatory success of companion diagnostics supporting targeted therapies, ensuring synchronized drug–diagnostic co-development from discovery through global registration and launch. Ensure companion diagnostics are fully integrated into clinical development plans with no downstream regulatory surprises, that drug and CDx approvals are synchronized globally, enabling seamless registrational and commercial execution. Help make the company a leader in targeted oncology CDx development. The role spans US, EU, and Asia-Pacific markets, with direct responsibility for aligning CDx development with clinical strategy, regulatory pathways, and commercialization plans. The successful candidate will operate as a strategic partner to Translational Sciences, Clinical Development, and Commercial partners.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
Ph.D. or professional degree